{
    "nct_id": "NCT03109977",
    "official_title": "First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies",
    "inclusion_criteria": "* Age 21 years or greater\n* Any biopsy proven HER2-positive malignancy. ASCO guidelines will be used to define HER2-positivity for breast cancer. Similar guidelines will be used for other cancer types as appropriate.\n* At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment\n* ECOG performance of 0-2\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* Life expectancy < 3 months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.",
    "miscellaneous_criteria": ""
}